• An Open Label Single Arm Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF Receptor Antibody, in Combination with Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma of the Head and Neck who have Failed Standard Platinum-Based Chemotherapy. (IRB# 3893)
  Sponsored by Genmab A/S.
  Institutional Principal Investigator: Neil Gross, M.D.
  
  
• Assessment of Known and Candidate Cancer Genes through DNA Analysis, RNA Expression and Protein Function Testing to Predict Patient Prognosis and Response to Current Standard and Experimental Therapies. (IRB# 809)
  Principal Investigator: Molly Kulesz-Martin, Ph.D
  Co-Investigator: Neil Gross, M.D.
  
  
• HPV Oral Transmission Study in Partners Over Time (HOTSPOT). (IRB #5263)
  Supported by the Johns Hopkins School of Public Health
  Principal Investigator: Neil Gross, M.D.
  
  
• M06-10083: Phase I Trial of Intratumoral Administration of HF10, a Replication-Competent Herpes Simplex Virus Type 1, in Patients with Refractory Head and Neck Cancer. (IRB #5265)
  Sponsored by M’s Science Corporation
  Principal Investigator: Neil Gross, M.D.
  
  
• OXiGENE OXC4T4-302: A Multicenter, Open-label, Randomized, Phase II/III Study to Evaluate the Safety and Efficacy of Combretastatin A-4 Phosphate in Combination with Paclitaxel and Carboplatin in Comparison with Paclitaxel and Carboplatin Against Anaplastic Thyroid Cancer. (IRB# 3821)
  Sponsored by OXiGENE
  Principal Investigator: Ann Gramza, M.D.
  Co-Investigator: Neil Gross, M.D.
  
  
• Phase 1/2 Study of CS-7017, and Oral PPARy Agonist, in Combination with Paclitaxel in Subjects with Advanced Anaplastic Thyroid Cancer (CS7017-A-U103) (IRB# 4274)
  Principal Investigator: Ann Gramza, M.D.
  Co-Investigator: Neil Gross, M.D.
  
  
• Prospective, Longitudinal, Multi-Center, Descriptive Registry of Patients Receiving Therapy other than Surgical Resection Alone for Newly Diagnosed Head and Neck Carcinoma. (IRB# 3914)
  Sponsored by ImClone, Inc.
  Principal Investigator: Neil Gross, M.D.
  
  
• RTOG 0514: Establishment of a Head and Neck Tissue/Specimen Bank. (IRB#2928)
  Supported by the National Cancer Institute
  Principal Investigator: Neil Gross, M.D.

• RTOG 0619: A Randomized Phase II Trial of Chemoradiotherapy versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck. (IRB #5140)
  Supported by the National Cancer Institute
  Principal Investigator: Neil Gross, M.D.

• Screening for Barrett's Metaplasia in Otolaryngology Patients
  Principal Investigator: Joshua Schindler, M.D.
  Co-Investigator with Blair Jobe, M.D.
  Department of Health and Human Services/Public Health Services
  
  
• UPCI 07-124: Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family Kinases Using Erlotinib and Dasatinib in Head and Neck and Lung Cancers. (IRB #5096)
  Supported by UPMC SPORE in head and neck cancer, University of Pittsburgh, OSI Pharmaceuticals, and Bristol-Meyers Squibb
  Principal Investigator: Neil Gross, M.D.
  
  
• Voice & Swallowing Outcomes after Cricotracheal Resection. IRB# 3336.
  Principal Investigator: James Cohen, M.D., Ph.D.
  Co-Investigators:
  Peter Andersen, M.D.
  Linda Bryans, M.A., CCC-SLP
  Andrew Palmer, M.S., CCC-SLP
  Joshua Schindler, M.D.